Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 17/20 | 0.73 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4590986 | 0.89 | TRPV1 (0.67) | TRPV1TRPV4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14083861 | 0.88 | TRPV1 (0.70) | TRPV1TRPV4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14083879 | 0.86 | TRPV1 (0.78) | TRPV1TRPV4 | |
| SCHEMBL3872091 | 0.86 | TRPV1 (0.78) | TRPV1TRPV4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6176039 | 0.86 | TRPV1 (0.67) | TRPV1TRPV4 | |
| SCHEMBL14082841 | 0.86 | TRPV1 (0.77) | TRPV1TRPV4 | |
| SCHEMBL14083898 | 0.86 | TRPV1 (0.70) | TRPV1TRPV4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14083542 | 0.86 | TRPV1 (0.70) | TRPV1TRPV4 | |
| SCHEMBL5934395 | 0.86 | TRPV1 (0.84) | TRPV1 | |
| SCHEMBL4808062 | 0.85 | TRPV1 (0.69) | TRPV1TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1673342-A2 | AMIDES THAT INHIBIT VANILLOID RECEPROT SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2006-06-28 | — | — | EP | claimed |
| US-7037927-B2 | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2006-05-02 | — | — | US | claimed |
| WO-2005040121-A2 | AMIDES THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2005-05-06 | — | — | WO | claimed |
| US-20050085512-A1 | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2005-04-21 | — | — | US | claimed |
| US-7595332-B2 | Amides that inhibit vanilloid receptor subtype 1 (VR1) | ABBOTT LABORATORIES (US) | 2009-09-29 | — | — | US | disclosed |
| EP-1673342-A2 | AMIDES THAT INHIBIT VANILLOID RECEPROT SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20060122231-A1 | Amides that inhibit vanilloid receptor subtype 1 (VR1) | ABBVIE INC. | 2006-06-08 | — | — | US | disclosed |
| US-7037927-B2 | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2006-05-02 | — | — | US | disclosed |
| WO-2005040121-A2 | AMIDES THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2005-05-06 | — | — | WO | disclosed |
| US-20050085512-A1 | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122231-A1 | Amides that inhibit vanilloid receptor subtype 1 (VR1) | TRPV1, OPRL1, AVPR2 | TRPV1 1/4885TRPV4 14/4885NPC1 4042/4885 |
| US-20050085512-A1 | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, OPRL1, AVPR1A | TRPV1 1/4885TRPV4 16/4885NPC1 3942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.